Here are the 10-K annual reports from Dare Bioscience, Inc. (DARE) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow DARE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DARE filings page.
Daré Bioscience outlines an expanded women’s health strategy in its annual report, combining traditional FDA drug development with Section 503B compounding and consumer health products. The company is beginning to commercialize proprietary formulations while advancing a diversified clinical pipeline.
Near term, Daré plans revenue from DARE to PLAY sildenafil cream, compounded via 503B outsourcing facilities, with dispensing expected in the second quarter of 2026, and from DARE to RESTORE Flora Sync LF5 vaginal probiotic suppositories, also targeted for U.S. launch in the second quarter of 2026. A second compounded product, DARE to estradiol progesterone intravaginal ring, is aimed for early 2027.
The report highlights progress on key clinical programs: Ovaprene, a hormone-free monthly contraceptive in a pivotal Phase 3 study; Sildenafil Cream, 3.6% for female sexual arousal disorder, preparing for Phase 3 after FDA feedback; DARE-HRT1, a bio-identical estradiol/progesterone ring heading toward Phase 3; DARE-HPV, backed by up to $10 million from ARPA-H and cleared for a Phase 2 IND; and additional programs like DARE-VVA1 for dyspareunia. Daré emphasizes partnerships, non-dilutive funding, and outsourced commercial infrastructure to reduce reliance on equity capital.